Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Nikkei retreats as investors lock in gains ahead of holiday

Published 04/28/2020, 11:42 AM
Updated 04/28/2020, 11:50 AM
© Reuters.
JP225
-
ESM24
-
JNIV
-
TOPX
-
6723
-
4062
-
4544
-
IMING.T
-
INFRO.T
-
ISTEL.T
-

SYDNEY, April 28 (Reuters) - Japanese stocks slipped on
Tuesday as investors booked profits after a sharp gain in the
previous session, though a raft of solid corporate earnings and
strong forecasts helped cap losses.
The benchmark Nikkei average .N225 was down 0.6% at
19,661.05 by midday break, a day after the index posted gains of
2.7% and ahead of the Showa Day holiday on Wednesday.
The Nikkei volatility index .JNIV , considered a fear gauge
based on option pricing, dropped as much as 11.3% to a
1-1/2-month low of 30.9, reflecting a drop in market anxiety.
E-Mini futures for the S&P 500 ESc1 dipped 0.4% in Asian
trade also created an extra headwind to Japanese shares.
Losses, however, were limited after companies reported
better-than-expected earnings or forecasts.
Ibiden Co Ltd 4062.T soared 15.1% after the electronic
components maker forecast a 37.2% increase in operating profit
for the current business year through March 2021. Renesas Electronics Corp 6723.T jumped 7.7% after the
maker of semiconductors for cars recorded a net profit of 11.3
billion yen ($105 million) for the January-March quarter - a
positive surprise for many analysts. The broader Topix .TOPX retreated 0.5% to 1,439.59 by the
midday recess, with all but six of the 33 sector sub-indexes on
the Tokyo exchange trading lower.
Highly cyclical iron and steel .ISTEL.T , mining .IMING.T
and non-ferrous metals .INFRO.T were the three
worst-performing sector sub-indexes on the main bourse.
Elsewhere, Miraca Holdings Inc 4544.T jumped 9% after the
diagnostics and laboratory testing service provider's subsidiary
Fujirebio applied for government approval for Japan's first
antigen coronavirus testing kits. Shionogi & Co Ltd 4507.T climbed 3.3% after the drug maker
announced a plan to develop a vaccine for the coronavirus, with
an aim to begin clinical trials later this year. = 107.2800 yen)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.